🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Members of the Bicara team participated in multiple presentations relating to ficerafusp alfa at the @aacr Annual Meeting 2025. These presentations highlight the broad therapeutic potential of ficerafusp alfa for solid tumors. Learn more about all the data presented here:

A head and neck #cancer diagnosis can be overwhelming, but patients deserve more than treatment—they deserve hope. We're developing next-generation biologics designed to precisely target tumors and reshape the tumor environment, striving for better outcomes with less burden on

Today, we announced our first quarter 2025 financial results and business update, highlighting continued execution across our clinical programs. For more details, read the full press release here: ir.bicara.com/news-releases/…

Today, we announced the publication of an abstract with updated interim data from our Phase 1/1b clinical trial of ficerafusp alfa in 1L R/M HNSCC on the ASCO website. We look forward to hosting a conference call on Sun, June 1, during #ASCO25 to share the fulsome dataset. To

#DYK that #headandneckcancer, can develop in multiple different places? Knowing the symptoms and staying proactive with regular check-ups are key to early detection. #HNSCC

Details: globenewswire.com/news-release/2… Today, we’re sharing updated data at #ASCO25 from the Phase 1/1b clinical trial of ficerafusp alfa in 1L HPV-negative R/M #HNSCC. These findings demonstrated deep & durable responses, translating to a median duration of response of 21.7 months, &

Following her oral presentation at #ASCO25, Christine Chung, MD (Christine Chung) shares updated results on ficerafusp alfa + pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma. Read the full abstract: meetings.asco.org/2025-asco-annu… #MoffittASCO25

CEO Claire Muzamdar met with @BiotechTVHQ's Brad Loncar at #ASCO25 to discuss data from our lead program, ficerafusp alfa, which is uniquely designed to penetrate the tumor and drive deep, durable responses. Claire shares more below.

Members of the Bicara management team will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 10. To access the live webcast and replay, visit our website at lnkd.in/gfy8e4NR

Are you or a loved one living with head and neck cancer? The FORTIFI-HN01 trial is a pivotal Phase 2/3 study evaluating a potential new treatment option and is currently enrolling patients. Bicara Therapeutics     clinicaltrials.gov/study/NCT06788…   #ClinicalTrial #HeadAndNeckCancer #CancerResearch

We're excited to announce that Claire Mazumdar has been appointed to our Board of Directors. As CEO of Bicara Therapeutics, Claire's expertise and perspective as the leader of a late-stage clinical biotech will complement our board well. Welcome, Claire!

We're thrilled to share that CEO Claire Muzamdar has been named a 2025 New England winner of the @EYNews #EntrepreneurOfTheYear award! This recognition is a testament to Claire's bold vision & unwavering commitment to transforming treatment for patients, which translates to a

This June, we recognize the more than 18 million in the U.S. who live with a history of cancer. That number is projected to reach 26 million by 2040. #NationalCancerSurvivorsMonth honors the strength and resilience of those impacted & highlights the importance of continued

Our CEO Claire Mazumdar joined Luke Timmerman on The Long Run podcast to talk about our bifunctional antibody for patients with HPV-negative HNSCC, how it sets Bicara apart, and what's ahead. Listen below. timmermanreport.com/2025/07/a-two-…

Strong science starts with strong people. Meet Pauline Dufresne, our Chief People Officer, who brings 18 years of HR experience, with the past decade in life sciences, to help scale Bicara with purpose and care. “Bicara’s culture of high integrity, perseverance, and respect

#DYK 1 in 3 kids in MA face clothing insecurity and may lack school-ready essentials? That’s why we teamed up with Life Science Cares & Cradles to Crayons Massachusetts to help by organizing backpacks, clothes, & supplies so local kids can start the school year strong. A powerful reminder that even “simple”